October 27, 2026
A New Jersey federal judge has upheld the U.S. Patent and Trademark Office's refusal to extend the life of a pair of patents on a cancer drug, rejecting a challenge from the patent owner that claimed the loss of exclusivity would cost it more than $1 billion.